[ad_1]
HONG KONG, March 1, 2022 /PRNewswire/ — Akeso, Inc. (9926.HK) (“Akeso”), a biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of new innovative antibody drugs that are affordable to patients worldwide announced that it entered into a collaboration agreement with Shenzhen Chipscreen Biosciences Co., Ltd., a company listed on the Shanghai Stock Exchange (Stock code: 688321.SH) (Chipscreen Biosciences) to establish a clinical trial partnership to jointly conduct a Phase Ib /II clinical trial of PD-1/CTLA-4 bi-specific cadonilimab in combination with Chiauranib for the treatment of first-line platinum-based chemotherapy in combination with PD-(L)1 inhibitor treatment regimen for extensive stage small cell lung cancer (ES-SCLC).
This cooperation is the specific practice of the Company in the 2.0 era of tumor immunity by adhering to the innovative drug development ideas of openness, diversity and win-win, cooperating with advantageous resources in the industry, deeply exploring the value of products. Leveraging on the advantages of the Chiauranib’s dual immunotherapy for oncology and the uniqueness of Chiauranib as a multi-pathway selective kinase inhibitor, the combination therapy is believed to bring more effective clinical benefits to patients in relevant studies of diseases such as lung cancer.
ABOUT CADONILIMAB (PD-1/CTLA-4 BI-SPECIFIC ANTIBODY, AK104)
Cadonilimab (PD-1/CTLA-4 bi-specific antibody, AK104) is a novel, first-in-class PD-1/ CTLA-4 bi-specific immuno-oncology backbone drug independently developed by the Company. Its main indications include lung cancer, liver cancer, gastric cancer, cervical cancer, kidney cancer, esophageal squamous cell cancer, nasopharyngeal carcinoma and other malignant tumors. According to the research phase data of relevant tumors, the toxicity of Cadonilimab is significantly reduced compared with the combination therapy of PD-1 and…
Full story available on Benzinga.com
[ad_2]
Source link